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ABSTRACT
The occurrence of methicillin-resistant Staphylococcus aureus (MRSA) is still increasing worldwide and is
associated with significant morbidity, mortality and hospital costs. Screening for MRSA plays a key role
in limiting further nosocomial spread of this organism. Control measures require a rapid and sensitive
test for direct detection of MRSA carriage. This study evaluated an easy-to-use PCR-hybridisation assay
for the direct detection of MRSA in clinical swab specimens. In total, 508 pairs of swabs from 242
patients at risk for MRSA carriage were analysed by the standard culture method and the PCR assay.
One swab was used for PCR and culture, while the second was used for culture only. Of the 508 pairs
tested, 37 were positive by culture and 35 were positive by PCR. Among the 471 culture-negative
specimens, 465 were negative by PCR and six were PCR-positive. The PCR assay had a sensitivity of
94.59%, a specificity of 98.73%, a positive predictive value of 85.37%, and a negative predictive value of
99.57%. The PCR-hybridisation assay enabled reliable detection of MRSA carriage in c. 4 h, thereby
allowing its effective use in an MRSA control strategy.
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INTRODUCTION
Staphylococcus aureus is one of the most important
human pathogens in terms of nosocomial and
community-acquired infections. Methicillin-resist-
ant S. aureus (MRSA) has spread worldwide, with
a mean prevalence among S. aureus blood culture
isolates during 2002 of 1% in The Netherlands,
19.2% in Germany, 44.5% in the UK [1] and 57.1%
among intensive care unit patients in the USA
[2,3]. The associated morbidity and mortality for
patients with MRSA infections is twice as high as
for patients with methicillin-susceptible S. aureus
(MSSA) infections [4]. In addition, the costs of
management of patients with MRSA infection are
1.5–3-fold higher than for patients with MSSA
infection [4,5]. In The Netherlands, studies have
shown that the spread of MRSA can be controlled
by implementing effective preventive measures,
and that these measures are cost-effective [2].
Screening of patients with risk-factors for MRSA
carriage is an important component of a successful
MRSA control policy [2,6]. In order to limit the
spread of MRSA, a rapid and sensitive test for
detection of MRSA colonisation is required. How-
ever, standard culture methods for identification
of MRSA require at least 48 h to complete. A
screening test for MRSA that provides accurate
results in less than a single day would enable
earlier MRSA control measures. A negative result,
embedded in a policy of screening upon admis-
sion and isolation of patients suspected of MRSA
carriage, would shorten the time of patient isola-
tion to <12 h and would therefore make the test
cost-effective.
Several DNA-based tests have been developed
for the rapid detection of MRSA. Most of these
tests are based on simultaneous detection of a
S. aureus-specific target and the mecA gene [7–10].
However, results may be non-specific when these
tests are used for direct detection of MRSA in
clinical specimens containing both coagulase-neg-
ative staphylococci (CoNS) and S. aureus, both of
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which can carry the mecA gene. By using MRSA-
specific chromosomal sequences, as described in
the present study, it is possible to detect MRSA
directly from clinical specimens, and to discrim-
inate MRSA from CoNS carrying the mecA gene.
MATERIALS AND METHODS
Analytical sensitivity and specificity of the nucleic
acid-based assay
The present study evaluated a PCR-based hybridisation assay
(GenoType MRSA Direct; Hain Lifescience, Nehren, Germany)
for the direct detection of MRSA from clinical swab specimens
obtained upon hospital admission from patients who had risk-
factors for MRSA carriage. GenoType MRSA Direct contains a
set of primers specific to staphylococcal cassette chromosome
mec (SCCmec) types I, II, III and IV, including the newly
recognised community-acquired MRSA strain. The results of
the test are available in c. 4 h.
The analytical sensitivity of the assay was evaluated using
22 MRSA isolates provided by the National Reference Centre
for Staphylococci, Wernigerode, Germany. The following
strains were tested: RKI ID 134 ⁄ 93 (ST 247); ID 3441 ⁄ 02
(ST 5); ID 1442 ⁄ 98 (ST 254); ID 1417 ⁄ 97 (ST 45); ID 809 ⁄ 96
(ST 134); ID 1155 ⁄ 98-2 (ST 228); ID 131 ⁄ 98 (ST 228);
ID 2594 ⁄ 97 (ST 228); ID 872 ⁄ 98 (ST 254); ID 1450 ⁄ 94 (ST 134);
ID 234 ⁄ 95 (ST 247); ID 406 ⁄ 98 (ST 247); ID 1678 ⁄ 96 (ST 22);
ID 1293 ⁄ 00 (ST 22); ID 773 ⁄ 96 (ST 239); ID 1000 ⁄ 93 (ST 254);
ID 3391 ⁄ 02 (ST 8); ID 2773 ⁄ 03 (ST 1); ID 1150 ⁄ 93 (ST 45);
ID 1816 ⁄ 03 (ST 30); ID 1085 ⁄ 04 (ST 8); and ID 949 ⁄ 04
(ST 254). These reference strains represent SCCmec types I, II,
III and IVa, c and d, and include the clonal lineages that are
prevalent among MRSA strains from infections in hospitals
and in the community in Europe and in North America [11].
The analytical specificity of the assay was determined using
53 methicillin-resistant CoNS and methicillin-susceptible
CoNS provided by the National Reference Centre for Staphy-
lococci, comprising 16 methicillin-resistant Staphylococcus epi-
dermidis, 14 methicillin-susceptible S. epidermidis, eight Staphy-
lococcus haemolyticus, and one each of the following
Staphylococcus spp.: S. hominis, S. lugdunesis, S. capitis, S. auri-
cularis, S. caprae, S. carnosus, S. cohnii, S. delphinii, S. equorum,
S. gallinarum, S. intermedius, S. sciurii, S. xylosus, S. warneri and
S. schleiferi. In addition, two MSSA strains were analysed,
including ATCC 25923, which is a S. aureus strain that carries
an SCCmec-type element lacking the mecA gene. This strain
carries a DNA fragment inserted at the same nucleotide
position in orfX as three different SCCmec elements, with
structural characteristics similar to SCCmec elements at both
ends that show high similarity to those of type III SCCmec [12].
The lower detection limit of the assay was determined by
serial dilution of four MRSA strains representing SCCmec
types I, II, III and IV, namely RKI ID 134 ⁄ 93 SCCmec type I,
RKI ID 3441 ⁄ 02 SCCmec type II, RKI ID 1442 ⁄ 98 SCCmec type
III, and RKI ID 1417 ⁄ 97 SCCmec type IV. After incubation for
24 h on Columbia blood agar, a suspension equivalent to a 0.5·
MacFarland standard was prepared in sterile NaCl 0.9% w ⁄v,
and then serially diluted in parallel in sterile NaCl 0.9% v ⁄v
and in lysis buffer (see below) to a final concentration of
10 CFU ⁄mL. Aliquots (500 lL) of each dilution were incubated
at 95C for 10 min, after which 5-lL portions were used for
PCRs (see below); 100 lL of each dilution were also plated on
Columbia blood agar and incubated at 37C for 24 h to
determine the number of CFUs.
Patient enrolment and collection of clinical specimens
Patients were selected at 12 hospitals (11 secondary- and
tertiary-care hospitals with 80–667 beds, and one hospital for
neurological long-term treatment with 102 beds). Patients were
considered for inclusion in the study if they had known risk-
factors for colonisation with MRSA, e.g., transfer from another
hospital or region with a high incidence of MRSA, antibiotic
treatment within the previous 14 days, or chronic wounds.
Patients were excluded from the study if they had received
treatment for MRSA colonisation or infection within the
previous 4 weeks. Two swabs (Venturi Transsystem, Copan,
Italy) were collected from each body site sampled of the
patients included in the study. In total, 508 pairs of swab
specimens were obtained from 242 patients between Novem-
ber 2004 and February 2005. The swabs were taken from the
following body sites: nose (n = 209), throat (n = 101), skin
(n = 80), groin (n = 46), axilla (n = 12), wound (n = 34) and
other sites (n = 26).
Processing of clinical specimens
One swab was initially agitated for 30 s in the lysis buffer
solution providedwith the assay andwas then used to inoculate
thioglycolate broth (Becton Dickinson, Heidelberg, Germany)
and Columbia-CNA agar (Becton Dickinson), containing sheep
blood 5% v ⁄v, colistin and nalidixic acid. The second swab was
used to inoculate thioglycolate broth and CNA agar only. CNA
agar plates were incubated for 48 h at 35C and then examined
for growth. The thioglycolate broths were incubated for 20–24 h
at 35C, subcultured to CNA agar, and examined for growth
after incubation for 20–24 h at 35C. The identification of
suspected S. aureus colonies was confirmed by tests with
clumping factor, protein A and a group-specific antigen bound
to S. aureus-specific peripheral structures (Slidex Staph Plus;
bioMe´rieux, Marcy-l’Etoile, France).
Confirmed S. aureus isolates were tested for growth on
oxacillin screen agar (Becton Dickinson) according to CLSI
recommendations [13]. Each isolate was also analysed using
the VITEK 2 instrument (bioMe´rieux), and MRSA was con-
firmed by detection of the mecA gene and a S. aureus-specific
target with the GenoType MRSA assay (Hain Lifescience).
GenoType MRSA Direct assay
DNA extraction and amplification. Specimens were processed for
PCR analysis according to the manufacturer’s instructions. The
swabs were washed in 300 lL of lysis buffer before cultivation.
Bacterial DNA was released by incubation of the lysis buffer
for 10 min at 95C, followed by centrifugation for 5 min at
6000 g. Portions (5 lL) of the supernatant were used for
amplification. In brief, 45 lL of primer nucleotide mix (provi-
ded with the kit), MgCl2 to a final concentration of 2.5 mM and
1 U of HotStarTaq polymerase (Qiagen, Hilden, Germany)
were added, followed by amplification on a PE 9700 thermo-
cycler (Applied Biosystems, Weiterstadt, Germany) for 15 min
at 95C, 35 cycles of 95C for 30 s, 55C for 40 s and 72C for
40 s, and a final extension at 70C for 8 min. Each run included
a negative control sample to demonstrate the absence of
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contaminating DNA. The sensitivity of amplification and
hybridisation was monitored using an internal control.
Hybridisation protocol. In brief, the assay uses a specific
oligonucleotide probe, targeting the SCCmec chromosomal
cassette of MRSA, that is immobilised on membrane strips.
PCR amplicons hybridise with this probe during the detec-
tion process. Hybridisation and detection were performed in
an automated washing and shaking device (Profiblot; Tecan,
Maennedorf, Switzerland). PCR products (20 lL) were mixed
for 5 min with 20 lL of denaturing reagent (provided with
the kit) at room temperature in separate troughs of a plastic
tray. After addition of 1 mL of pre-warmed hybridisation
buffer, the membrane strips in the kit were added to every
trough. Hybridisation was at 45C for 30 min, followed by
two washing steps at 45C for 30 min with 1 mL of pre-
warmed stringent wash solution. For colourimetric detection
of hybridised amplicons, streptavidin-conjugated alkaline
phosphatase and the appropriate substrate were added.
After final washing, the strips were air-dried and fixed on a
data sheet. The individual steps in the process, i.e., DNA
isolation, amplification and hybridisation, were monitored
using an internal control to improve the reliability of the
test.
RESULTS
Analytical sensitivity and specificity
All 22 MRSA reference strains, representing
SCCmec types I, II, III and IVa, c and d, including
the prevalent MRSA strains in Europe and North
America, tested positive by the GenoType MRSA
Direct assay. All 53 CoNS tested, including mecA-
positive CoNS, as well as two MSSA strains, were
negative. The lower detection limit of the assay
for serially diluted MRSA strains revealed a
detection limit of 20–30 CFU ⁄ 5 lL.
Clinical specimens
Of the 508 pairs of swabs tested, 37 were positive
by culture and 41 were positive by the GenoType
MRSA Direct assay. Thirty-five specimens posit-
ive by both culture and PCR were from 20
patients, of whom 12 had one specimen tested,
three had two specimens tested, three had three
specimens tested, and two had four specimens
tested. Table 1 summarises the efficiency of the
GenoType MRSA Direct assay in comparison
with culture for the detection of MRSA. In order
to resolve discrepant results, the assay was also
performed using the enrichment broths. Of the six
specimens from six patients that were PCR-
positive but culture-negative, none was culture-
positive after subculture from the enrichment
broth, but three remained PCR-positive. One of
these six patients had four other specimens taken
that were positive by both culture and PCR; the
other five patients had only one specimen taken.
Of the two specimens from two patients that were
PCR-negative but culture-positive, one specimen
remained PCR-negative, but two other specimens
from this patient were positive by both culture
and PCR. The other specimen was PCR-positive
when using the enrichment broth.
DISCUSSION
One important approach for controlling MRSA
transmission in hospitals involves the rapid iden-
tification of MRSA-carrying patients. Delays in
detection of MRSA lead to increased transmission
of MRSA among patients, higher numbers of
MRSA infections, and increased hospital costs.
The GenoType MRSA Direct assay provides a
rapid, sensitive and specific method, in compar-
ison with selective culture, for direct detection of
MRSA in clinical swab specimens. In combination
with a simple DNA extraction method and detec-
tion procedure, the results of the test are available
in c. 4 h.
A previous study used a commercially avail-
able PCR kit to detect MRSA directly from the
nasal swabs of 288 patients [14], and reported a
sensitivity of 91.7% and a specificity of 93.5%,
with a positive predictive value of 82.5% and a
negative predictive value of 97.1%. Huletsky et al.
[15,16] reported similar results with the same
system during a hospital surveillance programme
involving 331 nasal swab specimens from 162
patients at risk for MRSA colonisation, with a
sensitivity of 100%, a specificity of 96.5%, a
positive predictive value of 89.4% and a negative
predictive value of 100%. A higher number of
positive PCR results was found compared with
Table 1. Sensitivity and specificity of the GenoType
MRSA Direct assay in comparison with culture for the
detection of methicillin-resistant Staphylococcus aureus
Culture
GenoType MRSA













Positive 35 2 94.59 98.73 85.37 99.57
Negative 6 465
PPV, positive predictive value; NPV, negative predictive value.
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culture, perhaps because of the presence of non-
viable or non-cultivable MRSA, or an MRSA load
that was below the detection limit for the culture
method. More recently, a real-time PCR assay for
rapid identification of MRSA from clinical sam-
ples that targets the integration site (orfX) of the
SCCmec region has been described [17]. The assay
showed a sensitivity and specificity of 93% and
100%, respectively, when swabs were tested after
overnight incubation in brain–heart infusion
broth. The overnight incubation prolonged the
time required for a result to two working days.
The detection limit of the assay was <10 CFU ⁄
swab, compared with the 20–30 CFU ⁄ 5 lL
detected in the present study, but this did not
affect the clinical sensitivity.
One sample in the present study remained
PCR-negative after repetition of the assay, despite
the fact that the MRSA isolate from culture
carried the mecA gene, as shown in a separate
PCR for the mecA gene only (results not shown),
and the isolate itself was positive by the Geno-
Type MRSA Direct assay. Possibly, the number of
organisms present was below the detection limit
of the assay. The second swab was positive by
PCR after repeated testing.
The sensitivity of a direct DNA-based assay
may also be influenced by the type of swab. The
present study used a swab with a gel carrier and
charcoal, which is also suitable for culture. Fur-
ther studies are required to determine whether
the use of swabs suitable for culture methods is
optimal for direct DNA-based assays.
In conclusion, the GenoType MRSA Direct
assay appears to be a rapid, sensitive and specific
test for direct detection of MRSA in clinical swab
specimens, but simultaneous culture of the same
swab is recommended. The assay provides same-
day results, thereby improving the efficiency and
effectiveness of infection control measures to
prevent the spread of MRSA in a hospital setting.
Even a negative test result is cost-effective, as it
reduces the isolation time required for patients at
risk of MRSA carriage.
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